The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
275
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
The primary outcome measure is change in the Positive and Negative Syndrome Scale (PANSS) at Week 6 compared to baseline values.
The secondary measures assess both efficacy (cognition, depression) as well as a variety of safety/tolerability endpoints (adverse events, motor function, laboratory measures).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Anaheim, California, United States
GSK Investigational Site
Cerritos, California, United States
GSK Investigational Site
Garden Grove, California, United States
GSK Investigational Site
Glendale, California, United States
GSK Investigational Site
National City, California, United States
GSK Investigational Site
Oceanside, California, United States
GSK Investigational Site
Pico Rivera, California, United States
GSK Investigational Site
Rosemead, California, United States
GSK Investigational Site
San Diego, California, United States
...and 10 more locations